234 related articles for article (PubMed ID: 11900573)
41. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
[TBL] [Abstract][Full Text] [Related]
42. CyclinD1, a prominent prognostic marker for endometrial diseases.
Liang S; Mu K; Wang Y; Zhou Z; Zhang J; Sheng Y; Zhang T
Diagn Pathol; 2013 Aug; 8():138. PubMed ID: 23947899
[TBL] [Abstract][Full Text] [Related]
43. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
44. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
45. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
46. Benign endometrial proliferations mimicking malignancies: a review of problematic entities in small biopsy specimens.
Ip PP
Virchows Arch; 2018 Jun; 472(6):907-917. PubMed ID: 29445890
[TBL] [Abstract][Full Text] [Related]
47. Simultaneous immunohistochemical localization of beta-catenin and cyclin D1 in differentiated but not in undifferentiated human endometrial carcinoma.
Narita F; Sato A; Hamana S; Deguchi M; Otani T; Maruo T
Eur J Gynaecol Oncol; 2003; 24(2):129-34. PubMed ID: 12701961
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathological Characteristics and
Sung JY; Jung YY; Kim HS
Anticancer Res; 2018 May; 38(5):2779-2786. PubMed ID: 29715099
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma.
Shiozawa T; Nikaido T; Shimizu M; Zhai Y; Fujii S
Cancer; 1997 Dec; 80(12):2250-6. PubMed ID: 9404701
[TBL] [Abstract][Full Text] [Related]
50. Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H
Pathol Res Pract; 2007; 203(2):65-72. PubMed ID: 17258405
[TBL] [Abstract][Full Text] [Related]
51. Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium.
Zhou XH; Teng XD; Song WY; Wu YJ
Int J Gynecol Cancer; 2008; 18(1):152-8. PubMed ID: 17466050
[TBL] [Abstract][Full Text] [Related]
52. Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
Zhang D; Chen X; Xia H; Wang L; Zhao H; Xu B; Zhang A; Zhang W
BMC Cancer; 2020 Sep; 20(1):845. PubMed ID: 32883230
[TBL] [Abstract][Full Text] [Related]
53. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
54. Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis.
Mylonas I; Makovitzky J; Richter DU; Jeschke U; Briese V; Friese K
Gynecol Oncol; 2004 Apr; 93(1):92-7. PubMed ID: 15047219
[TBL] [Abstract][Full Text] [Related]
55. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
56. FHIT expression in neoplastic, hyperplastic, and normal endometrium.
Ozkara SK; Corakçi A
Int J Gynecol Cancer; 2005; 15(6):1081-8. PubMed ID: 16343185
[TBL] [Abstract][Full Text] [Related]
57. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium.
Nunobiki O; Taniguchi E; Ishii A; Tang W; Utsunomiya H; Nakamura Y; Mori I; Kakudo K
Pathol Int; 2003 Dec; 53(12):846-52. PubMed ID: 14629750
[TBL] [Abstract][Full Text] [Related]
58. 'Minimal deviation' endometrioid carcinoma with oncocytic change of the endometrium.
Mai KT; Yazdi HM; Boone SA
Arch Pathol Lab Med; 1995 Aug; 119(8):751-4. PubMed ID: 7544107
[TBL] [Abstract][Full Text] [Related]
59. Cytokeratin 19 expression in normal endometrium and in low-grade endometrioid adenocarcinoma of the endometrium.
Stewart CJ; Crook ML; Lacey J; Louwen K
Int J Gynecol Pathol; 2011 Sep; 30(5):484-91. PubMed ID: 21804393
[TBL] [Abstract][Full Text] [Related]
60. Stromal p16 expression is significantly increased in endometrial carcinoma.
Yoon G; Koh CW; Yoon N; Kim JY; Kim HS
Oncotarget; 2017 Jan; 8(3):4826-4836. PubMed ID: 27902476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
